Home/ Stocks/ AMLX

Amylyx Pharmaceuticals, Inc. Common Stock

AMLX XNAS

$14.73 -0.47 (-3.09%) ▼ 15-min delayed

Open

$15.20

High

$15.46

Low

$14.51

Volume

1.89M

Market Cap

$1.64B

About Amylyx Pharmaceuticals, Inc. Common Stock

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 136 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-41,284,000	$-0.37
FY 2025	$0	$-144,735,000	$-1.53
Q3 2025	$0	$-34,386,000	$-0.37
Q2 2025	$0	$-41,443,000	$-0.46

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for AMLX yet. Check out our latest market news or earnings calendar.

Get AMLX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Amylyx Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.